Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Gossamer Bio (GOSS) has announced the approval of inducement grants to three non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved non-qualified stock options to purchase up to 225,000 shares of common stock, effective January 6, 2025.
The options have an exercise price of $1.09 per share, matching the closing price of Gossamer’s stock on Nasdaq Global Select Market on January 6, 2025. These ten-year options will vest over four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments, contingent on continued employment.
Gossamer Bio (GOSS) ha annunciato l’approvazione di concessioni di incentivo per tre dipendenti non esecutivi nell’ambito del suo Piano di Incentivi all’Occupazione 2023. Il Comitato di Compensazione ha approvato opzioni su azioni non qualificate per l’acquisto di fino a 225.000 azioni di azioni ordinarie, con decorrenza dal 6 gennaio 2025.
Le opzioni hanno un prezzo di esercizio di $1,09 per azione, che corrisponde al prezzo di chiusura delle azioni di Gossamer sul mercato Nasdaq Global Select il 6 gennaio 2025. Queste opzioni, valide per dieci anni, matureranno in quattro anni, con il 25% che matura dopo un anno e il restante saldo che matura in 36 rate mensili, a condizione di continuare a lavorare.
Gossamer Bio (GOSS) ha anunciado la aprobación de concesiones de incentivo para tres empleados no ejecutivos bajo su Plan de Incentivos por Empleo 2023. El Comité de Compensación aprobó opciones de acciones no calificadas para la compra de hasta 225,000 acciones de acciones ordinarias, a partir del 6 de enero de 2025.
Las opciones tienen un precio de ejercicio de $1.09 por acción, coincidiendo con el precio de cierre de las acciones de Gossamer en el mercado Nasdaq Global Select el 6 de enero de 2025. Estas opciones de diez años se acumularán durante cuatro años, con el 25% acumulándose después de un año y el saldo restante acumulándose en 36 cuotas mensuales, condicionado a la continuidad del empleo.
고사머 바이오 (GOSS)는 2023 고용 유인 인센티브 상여 계획에 따라 세 명의 비상 executive 직원들에게 유인 보조금 승인을 발표했습니다. 보상위원회는 2025년 1월 6일부터 유효한 225,000주의 보통주 매수를 위한 비자격 주식 옵션을 승인했습니다.
옵션의 행사 가격은 $1.09 per 주로, 2025년 1월 6일 고사머 주식의 나스닥 글로벌 셀렉트 마켓에서의 종가와 일치합니다. 이 10년 만기 옵션은 4년에 걸쳐 발생하며, 1년 후 25%가 발생하고 나머지 잔액은 계속적인 고용 조건 하에 36개월에 걸쳐 발생합니다.
Gossamer Bio (GOSS) a annoncé l’approbation de primes d’incitation pour trois employés non exécutifs dans le cadre de son Plan d’Incitation à l’Emploi 2023. Le Comité de Rémunération a approuvé des options d’achat d’actions non qualifiées pour un total pouvant atteindre 225 000 actions ordinaires, à compter du 6 janvier 2025.
Les options ont un prix d’exercice de 1,09 $ par action, correspondant au prix de clôture de l’action de Gossamer sur le Nasdaq Global Select Market le 6 janvier 2025. Ces options de dix ans seront acquises sur une période de quatre ans, avec 25 % devenant acquises après un an et le reste en 36 paiements mensuels, sous réserve d’une poursuite de l’emploi.
Gossamer Bio (GOSS) hat die Genehmigung von Anreizgewährungen für drei nicht-executive Mitarbeiter im Rahmen seines 2023 Employment Inducement Incentive Award Plans bekannt gegeben. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Kauf von bis zu 225.000 Aktien zum 6. Januar 2025.
Die Optionen haben einen Ausübungspreis von $1,09 pro Aktie, was dem Schlusskurs der Gossamer-Aktie am Nasdaq Global Select Market am 6. Januar 2025 entspricht. Diese zehnjährigen Optionen werden über vier Jahre unverfallbar, wobei 25% nach einem Jahr und der verbleibende Rest in 36 monatlichen Raten unverfallbar, unter der Bedingung der fortgesetzten Anstellung.
Positive
- Stock options align employee interests with shareholders
- Structured vesting schedule promotes employee retention
SAN DIEGO–(BUSINESS WIRE)– Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 6, 2025, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 225,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.09 per share, which is equal to the closing price of Gossamer’s common stock as reported by The Nasdaq Global Select Market on January 6, 2025. The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive monthly installments thereafter, subject to each employee’s continued employment with Gossamer on such vesting dates. The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grants.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107942323/en/
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
Source: Gossamer Bio, Inc.
FAQ
What is the exercise price of GOSS stock options granted on January 6, 2025?
The stock options were granted with an exercise price of $1.09 per share, equal to GOSS’s closing price on Nasdaq Global Select Market on January 6, 2025.
How many shares are included in GOSS’s January 2025 inducement grants?
The inducement grants include options to purchase up to 225,000 shares of Gossamer Bio’s common stock.
What is the vesting schedule for GOSS’s January 2025 inducement grants?
The options vest over four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments, subject to continued employment.
How long is the term of GOSS’s January 2025 stock option grants?
The stock options have a ten-year term from the grant date of January 6, 2025.
